Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jena Leisher

Nurse Practitioner Lancaster, PA Nurse Practitioner

NPI 1831737519 CMS profile 10450323

40 Pearl St, Lancaster, PA 17603

Open in the dashboard

General payments

$5,930

256 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jena Leisher of Lancaster, PA is reported in the CMS Open Payments database as having received $5,930 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,324 57
2024 General $967 48
2023 General $1,324 51
2022 General $1,427 65
2021 General $889 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jena Leisher
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jena Leisher were reported at $1,324. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jena Leisher Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $889 $135 $40–$426 $132
2022 $1,427 $152 $48–$470 $149
2023 $1,324 $166 $54–$529 $160
2024 $967 $173 $55–$556 $164
2025 $1,324 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,078 54 payments
  2. ITI, Inc. $989 30 payments
  3. Alkermes, Inc. $851 30 payments
  4. Otsuka America Pharmaceutical, Inc. $735 31 payments
  5. Neurocrine Biosciences, Inc. $637 29 payments
  6. Supernus Pharmaceuticals, Inc. $402 17 payments
  7. Axsome Therapeutics, Inc. $317 14 payments
  8. Lundbeck LLC $270 16 payments
  9. Janssen Pharmaceuticals, Inc $179 10 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $159 9 payments
  11. Other $314 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,873 253 payments
  2. Education $58 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $892 45 payments
  2. CAPLYTA $755 21 payments
  3. LYBALVI Cns $751 29 payments
  4. LYBALVI Cns $674 25 payments
  5. LYBALVI Cns $628 21 payments
  6. LYBALVI Cns $628 21 payments
  7. INGREZZA $549 24 payments
  8. ABILIFY MAINTENA $457 19 payments
  9. ABILIFY ASIMTUFII $336 8 payments
  10. REXULTI $334 17 payments
  11. Other $2,886 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

268

Median for Nurse Practitioner: 389

Drug cost

$8,310

Median for Nurse Practitioner: $21,885

Branded share of claims

19.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belsomra Suvorexant Brand 12 $4,859
Duloxetine Hcl Generic 24 $607
Bupropion Xl Bupropion Hcl Brand 29 $441
Olanzapine Generic 13 $395
Ziprasidone Hcl Generic 14 $372
Trazodone Hcl Generic 28 $369
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 12 $321
Mirtazapine Generic 16 $208
Quetiapine Fumarate Generic 16 $207
Aripiprazole Generic 20 $204

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $203
$203 — —
CAPLYTA
  • ITI, Inc. $182
$182 — —
Auvelity
  • Axsome Therapeutics, Inc. $170
$170 — —
VRAYLAR
  • AbbVie, Inc. $148
$148 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $44
  • Lundbeck LLC $44
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record